SCHEMBL5889545

SCHEMBL5889545

Cn1cc(NC(=O)c2ccc3[nH]c(C(=O)Nc4cc(C(=O)NCCN5CCNCC5)n(C)c4)cc3c2)cc1C(=O)NCCN1CCNCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRAS P01112 4/20 0.53
ESR1 P03372 4/20 0.53
ESR2 Q92731 4/20 0.53
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 2/20 0.47
MAPT P10636 1/20 0.47
HSD17B10 Q99714 2/20 0.46
CCNT1 O60563 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
CDK9 P50750 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
AURKB Q96GD4 1/20 0.44
ROCK2 O75116 2/20 0.43
PARP1 P09874 1/20 0.43
HASPIN Q8TF76 4/20 0.42
HTR4 Q13639 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889571 0.85 HRAS (0.59) HRASESR1ESR2KDM4EMAPT
SCHEMBL5889539 0.83 HRAS (0.60) HRASESR1ESR2ROCK2PARP1
SCHEMBL5889560 0.80 HRAS (0.54) HRASESR1ESR2ROCK2PLD2
SCHEMBL5889831 0.80 NHERF1 (0.53) HRASESR1ESR2KDM4EPLD2
SCHEMBL5889566 0.78 HRAS (0.53) HRASESR1ESR2ROCK2PLD2
SCHEMBL5889480 0.78 KDM4E (0.49) HRASESR1ESR2KDM4EALDH1A1
SCHEMBL6779947 0.74 HRAS (0.52) HRASESR1ESR2KDM4EALDH1A1
SCHEMBL5889540 0.74 PLD2 (0.46) HRASESR1ESR2KDM4EALDH1A1
SCHEMBL12514061 0.72 EPHX2 (0.55) ALDH1A1HDAC2HDAC8HDAC6
SCHEMBL14509954 0.72 HDAC1 (0.43) HRASESR1ESR2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064218-B2 Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2006-06-20 US disclosed
US-6906103-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-06-14 US disclosed
US-6849713-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-02-01 US disclosed
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GLAXOSMITHKLINE LLC 2003-11-13 US disclosed
WO-2003057212-A1 POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-07-17 WO disclosed
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity SMITHKLINE BEECHAM CORPORATION 2003-06-26 US disclosed
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. 2002-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 HRAS 402/4885ESR1 4097/4885ESR2 3377/4885
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 HRAS 402/4885ESR1 4097/4885ESR2 3377/4885
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity TYR, CYP51A1, ODC1 HRAS 1040/4885ESR1 4541/4885ESR2 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.